Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regadenoson Dose Finding for BBB Disruption in High Grade Glioma
NCT03971734Phase 1Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Dec 2019
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of regadenoson in high-grade glioma (HGG) (7 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Dose of regadenoson at 15 minutes and Gadolinium Ktrans at 15 minutes. Started Dec 2019; status: terminated.
02
Drugs
regadenoson
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT03971734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971734.